


Stereocontrolled Total Syntheses of ( $\pm$ )-Fawcettimine, ( $\pm$ )-Lycoflexine, and ( $\pm$ )-Lycoflexine N-OxideKe Xu,<sup>†</sup> Bin Cheng,<sup>†</sup> Yun Li,<sup>†</sup> Tingting Xu,<sup>†</sup> Cunming Yu,<sup>†</sup> Jun Zhang,<sup>†</sup> Zhiqiang Ma,<sup>‡</sup> and Hongbin Zhai<sup>\*,†</sup><sup>†</sup>The State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000, China<sup>‡</sup>Division of Chemistry, Department of Biochemistry, The University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9038, United States

## S Supporting Information



**ABSTRACT:** New stereocontrolled total syntheses of ( $\pm$ )-fawcettimine, ( $\pm$ )-lycoflexine, and ( $\pm$ )-lycoflexine N-oxide have been accomplished. The highlights include a one-pot annulation to construct the enedione and a microwave-promoted Diels–Alder reaction.

Since the isolation of fawcettimine (**1**) from *Lycopodium fawcetti* by Burnell in 1959,<sup>1</sup> about 90 members of *Lycopodium* alkaloids<sup>2</sup> have been discovered over the past decades (Figure 1).



Figure 1. Structures of 1–3.


Fawcettimine, an important biogenetic precursor of other *Lycopodium* alkaloids, possesses a unique 6/5/7/6 tetracyclic skeleton embedded with five stereogenic centers including an all-carbon quaternary one. Due to its structural complexity and potent acetylcholine esterase inhibitory activity,<sup>3</sup> this alkaloid has become an attractive target for the synthetic community. To date, 11 total syntheses,<sup>4a–k</sup> one formal synthesis,<sup>4l</sup> and one synthetic study<sup>4m</sup> have been reported.

Lycoflexine (**2**) was proposed to be derived biogenetically from fawcettimine via Mannich cyclization and was first isolated from *Lycopodium clavatum* var. *Inflexum*.<sup>5</sup> Its intriguing structure consists of a 6/5/7/6 tetracyclic skeleton and four stereogenic centers including two adjacent quaternary carbons. Since the first total synthesis by Ramharter and co-workers,<sup>6</sup> three unified routes have been developed for the total syntheses of fawcettimine and lycoflexine in 16–22 steps.<sup>4g,i,j</sup>

Lycoflexine N-oxide (**3**) was recently isolated from three species of *Lycopodium* (i.e., *Lycopodium clavatum*, *Lycopodium serratum*, and *Lycopodium squarrosum*) and a semisynthesis of **3** has been accomplished by Takayama and co-workers.<sup>7</sup>

In this paper, we report a unified strategy for the stereocontrolled assembly of fawcettimine (**1**), lycoflexine (**2**), and lycoflexine N-oxide (**3**). As outlined in Scheme 1, alkaloids 1–3 could be derived from the common intermediate **4**. We envisioned that **4** should be accessible through Diels–Alder reaction of **6** followed by a formal three-atom ring

## Scheme 1. Retrosynthetic Analysis of 1–3




Received: November 4, 2013

Published: December 2, 2013

expansion. Dienophile **6** may be generated from aldehyde **7**, which could be readily prepared from enone **8** and bis-silane **9**. It is worth noting that the Diels–Alder reaction has been utilized to construct the A ring<sup>4i</sup> (see Figure 1 for the ring codes) and B ring<sup>4a</sup> of fawcettimine. However, this cycloaddition reaction has never been used for assembling the C ring within fawcettimine or its related alkaloids.

Sakurai alkylation<sup>4c,d,8</sup> of **8**<sup>9</sup> with **9**<sup>10</sup> was utilized to introduce a desirable side chain at C1, providing alcohol **10** essentially as a single isomer (Scheme 2). Oxidation of **10** with

Scheme 2. Synthesis of **6**



PDC in DCM furnished aldehyde **7** in high yield. The hydrindanone core of **6** could potentially be obtained from **7** via an intramolecular aldol reaction. The transformation was initially carried out with a Brønsted acid (TsOH or camphorsulfonic acid) as a catalyst, but an undesired product (either **11a** or **11b**) was formed (path A). When compound **7** was treated with KOH in EtOH and H<sub>2</sub>O followed by a selectively oxidative cleavage of the terminal olefin within **12** (path B), the desired product **6** could be obtained but only in 9% overall yield. After various attempts, we were pleased to find that the overall yield of enedione **6** could be increased to 40% if **7** was subjected sequentially to dihydroxylation, aldol reaction, and oxidative cleavage of the vicinal diol unit in a one-pot fashion (path C). In contrast, **6** could not be generated from aldehyde **7** through sequential alkene cleavage (OsO<sub>4</sub>/NaIO<sub>4</sub> or O<sub>3</sub>)/aldol reaction, presumably due to the poor stability of the  $\alpha$ -carbonyl aldehyde intermediate (path D).<sup>11</sup>

With compound **6** in hand, the Diels–Alder reaction was extensively investigated under a series of conditions (Table 1). Initially, 3-sulfolene was chosen as a diene precursor, from which 1,3-butadiene could be produced in situ.<sup>12a</sup> Unfortunately, enedione **6** was completely decomposed in various solvents (PhH, DCM, or MeOH), even in the presence of an excess amount of base, presumably due to the adverse effect of SO<sub>2</sub>, the byproduct of the thermal cracking of 3-sulfolene at high temperature (Table 1, entries 1–4). 1,3-Butadiene was

Table 1. Diels–Alder Reaction of **6** with 1,3-Butadiene or Its Precursor<sup>a</sup>

entry	diene	solvent	temp (°C)	t (h)	additives (equiv)	yield <sup>b</sup> (%)
1	3-sulfolene	PhH	120	8	quinol (0.2)	—
2	3-sulfolene	DCM	120	8	quinol (0.2)	—
3	3-sulfolene	MeOH	120	8	quinol (0.2)	—
4	3-sulfolene	PhH	120	8	quinol (0.2), Py (3), NaHCO <sub>3</sub> (3)	—
5 <sup>c</sup>	butadiene	PhMe	120	24	BHT (0.2)	NR
6 <sup>d</sup>	butadiene	PhMe	120	10	BHT (0.2)	39
7 <sup>d</sup>	butadiene	PhMe	140	50	BHT (0.2)	58
8 <sup>d,e</sup>	butadiene	PhMe	110	11	BHT (0.2)	79

<sup>a</sup>All reactions were performed in a sealed tube. <sup>b</sup>Isolated yields.


<sup>c</sup>Concentration of 1,3-butadiene in PhMe was 1.5 mM. <sup>d</sup>Concentration of 1,3-butadiene in PhMe was 30 mM. <sup>e</sup>Performed in a microwave reactor. BHT: 2,6-di-*tert*-butyl-4-methylphenol.

subsequently used in the reaction instead of 3-sulfolene.<sup>12b</sup> No reaction took place when a low concentration ( $c = 1.5$  mM) of 1,3-butadiene was heated with **6** in PhMe at 120 °C; however, adduct **5** could be stereoselectively formed in 39% yield (or 84%, brsm) with higher 1,3-butadiene concentration ( $c = 30$  mM) at the same temperature (entries 5–6). The stereoselectivity observed for the formation of **5** should result from steric control. A much higher temperature (140 °C) and longer reaction time (50 h) led to an even better yield (58%, entry 7). Gratifyingly, the yield could be further improved to 79% by performing the cycloaddition in a microwave reactor while the reaction time was reduced to 11 h (entry 8).<sup>12c</sup> Note that the Diels–Alder reaction of **6** with 1,3-butadiene conducted in the presence of either a Brønsted acid (CF<sub>3</sub>CO<sub>2</sub>H) or a Lewis acid (TiCl<sub>4</sub>, TMSOTf, or Me<sub>2</sub>AlCl) proved to be unsuccessful.<sup>12d</sup>


With the consideration of double N-alkylation at a later stage in mind, protection of both carbonyl groups in **5** gave bis-acetal **14**, the structure of which was confirmed by X-ray crystallographic analysis. Compound **14** was transformed into bisiodide **17** in 53% overall yield after a four-step reaction sequence: (a) oxidative cleavage of the carbon–carbon double bond, (b) Wittig reaction of both formyl groups, (c) hydroboration/oxidation of both terminal alkene units, and (d) iodination of both hydroxyl groups. However, the attempted double N-alkylation of NsNH<sub>2</sub> with **17** was unsuccessful; the diiodide substrate decomposed in the presence of a base such as K<sub>2</sub>CO<sub>3</sub>, NaOH, or Cs<sub>2</sub>CO<sub>3</sub>.

The acetal protecting groups might adversely affect the above-mentioned double alkylation of NsNH<sub>2</sub> with **17** (Scheme 3). Subsequently, we resorted to a different protection approach for the carbonyl groups in **5**. As described in Scheme 4, stereoselective reduction of diketone **5** with NaBH<sub>4</sub> afforded diol **18** (62%) and other stereoisomers (30%); the latter were oxidized with DMP to regenerate **5** for the purpose of recycling. Protection of both hydroxyl groups in **18** resulted in compound **19**, where the relative configurations of C3 and C13 were speculated on the basis of NOE experiments. Through similar transformations applied to **14**, alkene **19** was converted smoothly into diol **20** in three steps including (a) oxidative

Scheme 3. Synthesis of Diiodide 17




Scheme 4. Synthesis of 22a



cleavage, (b) Wittig reaction, and (c) hydroboration/oxidation. Unfortunately, all attempts to effect double Fukuyama–Mitsunobu reactions<sup>13</sup> of **20** under various conditions with  $\text{NsNH}_2$  produced only a complex mixture. Then, sulfonation of both hydroxyl groups in **20** furnished dimesylate **21** in 92% yield. To our delight, double N-alkylation did take place when **21** was treated with  $\text{NsNH}_2$  (1.4 equiv), aqueous NaOH solution, and tetrabutylammonium iodide in benzene/DMF at 110 °C. The desired tricycle **22a** was produced in 58% yield along with a small amount (7%) of bis-sulfonamide **22b**.<sup>4g,i,j,14</sup>

Removal of both MOM groups in **22a** followed by Ley oxidation of **23** led to the key intermediate **4** in 84% overall yield (Scheme 5). Upon desulfonation of **4**, fawcettimine (**1**) was afforded in 85% yield after spontaneous epimerization at C4 and amination formation.<sup>4i,j</sup> Lycoflexine (**2**) was obtained from **4** in 88% yield via a one-pot desulfonation/Mannich reaction.<sup>4i</sup>

Scheme 5. Completion of the Total Syntheses of 1–3



Upon treatment with MCPBA in DCM (−10 °C), lycoflexine (**2**) was cleanly converted into lycoflexine N-oxide (**3**) in 10 min (as monitored by TLC).<sup>7</sup> The spectroscopic data of the synthetically obtained (±)-fawcettimine (**1**), (±)-lycoflexine (**2**), and (±)-lycoflexine N-oxide (**3**) were identical to those reported in the literature.<sup>4a–k,5–7</sup>

In summary, we have developed a unified strategy for the total syntheses of fawcettimine (**1**), lycoflexine (**2**), and lycoflexine N-oxide (**3**) from (±)-**8** in 14, 14, and 15 steps, respectively. Although the total syntheses reported herein are those of racemic **1–3**, it would be straightforward to realize their asymmetric syntheses by starting with optically active (5*R*)-5-methylcyclohex-2-enone [(5*R*)-**8**].<sup>15</sup> The key features of the current strategy include a one-pot annulation of **7** to construct fused 6/5 bicyclic enedione **6** and a microwave-promoted Diels–Alder reaction of **6** to assemble key intermediate **5** with the C12 quaternary center installed in place.

## ■ ASSOCIATED CONTENT

### Supporting Information

Experimental procedures and characterization data for new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## ■ AUTHOR INFORMATION

### Corresponding Author

\*E-mail: zhaih@lzu.edu.cn.

### Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

We thank the National Basic Research Program of China (973-2010CB833200), NSFC (21172100; 21272105; 21290180), Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT: IRT1138), FRFCU (lzujbky-2013-ct02), and the “111” Program of MOE for financial support.

## ■ REFERENCES

- (a) Burnell, R. H. *J. Chem. Soc.* **1959**, 3091. (b) Burnell, R. H.; Mootoo, B. S. *Can. J. Chem.* **1961**, *39*, 1090.

- (2) (a) Ma, X.; Gang, D. R. *Nat. Prod. Rep.* **2004**, *21*, 752. (b) Hirasawa, Y.; Kobayashi, J.; Morita, H. *Heterocycles* **2009**, *77*, 679.
- (3) (a) Kobayashi, J.; Morita, H. In *The Alkaloids*; Cordell, G. A. E., Ed.; Academic Press: New York; 2005; Vol. 61, pp 1–57. (b) He, X. C.; Feng, S.; Wang, Z. F.; Shi, Y.; Zheng, S.; Xia, Y.; Jiang, H.; Tang, X. C.; Bai, D. *Bioorg. Med. Chem.* **2007**, *15*, 1394.
- (4) (a) Harayama, T.; Takatani, M.; Inubushi, Y. *Tetrahedron Lett.* **1979**, *20*, 4307. (b) Harayama, T.; Takatani, M.; Inubushi, Y. *Chem. Pharm. Bull.* **1980**, *28*, 2394. (c) Heathcock, C. H.; Smith, K. M.; Blumenkopf, T. A. *J. Am. Chem. Soc.* **1986**, *108*, 5022. (d) Heathcock, C. H.; Blumenkopf, T. A.; Smith, K. M. *J. Org. Chem.* **1989**, *54*, 1548. (e) Linghu, X.; Kennedy-Smith, J. J.; Toste, F. D. *Angew. Chem., Int. Ed.* **2007**, *46*, 7671. (f) Otsuka, Y.; Inagaki, F.; Mukai, C. *J. Org. Chem.* **2010**, *75*, 3420. (g) Yang, Y.; Shen, L.; Huang, J.; Xu, T.; Wei, K. *J. Org. Chem.* **2011**, *76*, 3684. (h) Li, H.; Wang, X.; Lei, X. *Angew. Chem., Int. Ed.* **2012**, *51*, 491. (i) Pan, G.; Williams, R. M. *J. Org. Chem.* **2012**, *77*, 4801. (j) Itoh, N.; Iwata, T.; Sugihara, H.; Inagaki, F.; Mukai, C. *Chem.—Eur. J.* **2013**, *19*, 8665. (k) Huo, S. H.; Tu, Y. Q.; Liu, L.; Zhang, F. M.; Wang, S. H.; Zhang, X. M. *Angew. Chem., Int. Ed.* **2013**, *52*, 11373. (l) Liu, K.; Chau, C.; Sha, C. *Chem. Commun.* **2008**, 91. (m) Jung, M. E.; Chang, J. J. *Org. Lett.* **2010**, *12*, 2962.
- (5) Ayer, W. A.; Fukazawa, Y.; Singer, P. P.; Altenkirk, B. *Tetrahedron Lett.* **1973**, *14*, 5045.
- (6) Ramharter, J.; Weinstabl, H.; Mulzer, J. *J. Am. Chem. Soc.* **2010**, *132*, 14338.
- (7) Katakawa, K.; Mito, H.; Kogure, N.; Kitajima, M.; Wongseripipatana, S.; Arisawa, M.; Takayama, H. *Tetrahedron* **2011**, *67*, 6561.
- (8) (a) Hosomi, A.; Sakurai, H. *J. Am. Chem. Soc.* **1977**, *99*, 1673. (b) Sakurai, H. *Pure Appl. Chem.* **1982**, *54*, 1. (c) Blumenkopf, T. A.; Heathcock, C. H. *J. Am. Chem. Soc.* **1983**, *105*, 2354.
- (9) For the preparation of **8**, see: (a) Chong, B.; Oh, Y. J. S.; Yang, J.; Baik, W.; Koo, S. *J. Org. Chem.* **1997**, *62*, 9323. (b) Watson, I. D. G.; Yudin, A. K. *J. Am. Chem. Soc.* **2005**, *127*, 17516.
- (10) For the preparation of **9**, see: (a) Trost, B. M.; Chan, D. M. T. *J. Am. Chem. Soc.* **1983**, *105*, 2315. (b) Trost, B. M.; Chan, D. M. T.; Nanninga, T. N. *Org. Synth.* **1984**, *62*, 58.
- (11) Danishefsky, S.; Etheredge, S. J. *J. Org. Chem.* **1982**, *47*, 4791.
- (12) For representative examples, see: (a) Kotha, S.; Chavan, A. S.; Dipak, M. K. *Tetrahedron* **2011**, *67*, 501. (b) Dolb, L. J.; Esfandiari, S.; Elliger, C. A.; Marshall, K. S. *J. Org. Chem.* **1971**, *36*, 1277. (c) Zaimoku, H.; Nishide, H.; Nishibata, A.; Goto, N.; Taniguchi, T.; Ishibashi, H. *Org. Lett.* **2013**, *15*, 2140. (d) Solladié, G.; Lohse, O. *J. Org. Chem.* **1993**, *58*, 4555.
- (13) (a) Mitsunobu, O.; Yamada, M. *Bull. Chem. Soc. Jpn.* **1967**, *40*, 2380. (b) Yet, L. *Chem. Rev.* **2000**, *100*, 2963. (c) Kaburagi, Y.; Tokuyama, H.; Fukuyama, T. *J. Am. Chem. Soc.* **2004**, *126*, 10246.
- (14) Shimada, N.; Abe, D. Y.; Yokoshima, D. S.; Fukuyama, T. *Angew. Chem., Int. Ed.* **2012**, *51*, 11824.
- (15) For preparation of (5*R*)-5-methylcyclohex-2-enone, see: (a) Fleming, I.; Maiti, P.; Ramarao, C. *Org. Biomol. Chem.* **2003**, *1*, 3989. (b) Carlone, A.; Marigo, M.; North, C.; Landa, A.; Jørgensen, K. A. *Chem. Commun.* **2006**, 4928.